News

The board of Cipla at its meeting held on 23 July 2026 has approved the following:Transition of Ashish Adukia, Global Chief Financial Officer, to internal business leadership role. Consequent to such transition, Ashish Adukia has relinquished the position as the Global Chief Financial Officer and Key Managerial Personnel (KMP) of the Company with effect from close of business hours of 23 July 2026. Appointment of Dinesh Jain, Chief - Corporate Finance, as Global Chief Financial Officer and KMP with effect from 24 July 2026.

Cipla has granted 24,709 stock options and employee stock appreciation rights on 23 July 2026.

Net profit of Cipla declined 39.19% to Rs 789.05 crore in the quarter ended June 2026 as against Rs 1297.62 crore during the previous quarter ended June 2025. Sales rose 3.51% to Rs 7077.02 crore in the quarter ended June 2026 as against Rs 6837.04 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales7077.026837.04 4 OPM %16.8526.01 - PBDT1386.172022.65 -31 PBT1081.931769.93 -39 NP789.051297.62 -39 Powered by Capital Market - Live News

Cipla announced that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the company) located in Central Islip, Long Island, New York, USA, from 13 July 2026 to 17 July 2026 (EDT). The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. On conclusion of the inspection, the company has received 1 (one) inspectional observation in Form 483. Powered by Capital Market - Live News

Cipla announced that ESG Risk Assessments & Insights Limited, a SEBI registered ESG Rating Provider (ESGRisks.ai), has revised the Company`s ESG rating from 68 to 64. The revision is based on re-evaluation of publicly available information and certain new information considered during the assessment period.